NASDAQ:PULM Pulmatrix (PULM) Stock Price, News & Analysis $8.92 -0.09 (-1.00%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$9.10 +0.18 (+1.96%) As of 02/21/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Pulmatrix Stock (NASDAQ:PULM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pulmatrix alerts:Sign Up Key Stats Today's Range$8.81▼$9.3550-Day Range$5.76▼$10.0252-Week Range$1.55▼$10.40Volume20,434 shsAverage Volume35,780 shsMarket Capitalization$32.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Read More… Pulmatrix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScorePULM MarketRank™: Pulmatrix scored higher than 2% of companies evaluated by MarketBeat, and ranked 953rd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pulmatrix. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmatrix is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmatrix is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmatrix has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pulmatrix's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.45% of the float of Pulmatrix has been sold short.Short Interest Ratio / Days to CoverPulmatrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmatrix has recently increased by 10.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulmatrix does not currently pay a dividend.Dividend GrowthPulmatrix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.45% of the float of Pulmatrix has been sold short.Short Interest Ratio / Days to CoverPulmatrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmatrix has recently increased by 10.90%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for PULM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pulmatrix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.62% of the stock of Pulmatrix is held by insiders.Percentage Held by InstitutionsOnly 11.84% of the stock of Pulmatrix is held by institutions.Read more about Pulmatrix's insider trading history. Receive PULM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter. Email Address PULM Stock News HeadlinesPulmatrix revises bylaws, changes voting standardsFebruary 14, 2025 | msn.comCullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic PainJanuary 23, 2025 | finance.yahoo.com$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.February 22, 2025 | Altimetry (Ad)SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 14, 2024 | globenewswire.comPulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed MergerNovember 14, 2024 | finanznachrichten.dePulmatrix Shares Surge on Merger with CullgenNovember 14, 2024 | marketwatch.comPulmatrix Shares Hit 52-Week High After News of Merger DealNovember 14, 2024 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 14, 2024 | globenewswire.comSee More Headlines PULM Stock Analysis - Frequently Asked Questions How have PULM shares performed this year? Pulmatrix's stock was trading at $6.98 at the beginning of the year. Since then, PULM shares have increased by 27.8% and is now trading at $8.92. View the best growth stocks for 2025 here. How were Pulmatrix's earnings last quarter? Pulmatrix, Inc. (NASDAQ:PULM) posted its earnings results on Friday, November, 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.37 million for the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 45.97% and a negative net margin of 96.51%. When did Pulmatrix's stock split? Shares of Pulmatrix reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Pulmatrix's major shareholders? Top institutional investors of Pulmatrix include Renaissance Technologies LLC (2.99%), SBI Securities Co. Ltd. (1.81%), Geode Capital Management LLC (1.01%) and Concourse Financial Group Securities Inc.. View institutional ownership trends. How do I buy shares of Pulmatrix? Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pulmatrix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE). Company Calendar Last Earnings11/08/2024Today2/22/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PULM CUSIPN/A CIK1574235 Webwww.pulmatrix.com Phone(781) 357-2333Fax707-525-9906Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,120,000.00 Net Margins-96.51% Pretax Margin-96.51% Return on Equity-45.97% Return on Assets-30.72% Debt Debt-to-Equity RatioN/A Current Ratio19.40 Quick Ratio19.40 Sales & Book Value Annual Sales$7.30 million Price / Sales4.46 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book1.81Miscellaneous Outstanding Shares3,650,000Free Float3,629,000Market Cap$32.56 million OptionableNot Optionable Beta1.61 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:PULM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.